LUYE PHARMA (02186) rose nearly 3%, with a gain of 2.66% at the time of writing, trading at HK$3.09 and a turnover of HK$8.3751 million. On December 7, LUYE PHARMA announced that five of its new products have been successfully included in either the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)" (National Reimbursement Drug List) or the "Commercial Health Insurance Innovative Drug Directory (2025)" (Commercial Insurance Innovative Drug Directory), both issued by the National Healthcare Security Administration.

The five new products include Mimexin® (oxycodone-naloxone prolonged-release tablets) and Ruibailai® (paliperidone palmitate injection (II)), which were newly added to the National Reimbursement Drug List. Zanbijia® (lurbinectedin for injection) was successfully selected for the Commercial Insurance Innovative Drug Directory. Meanwhile, Baitowei® (goserelin acetate microspheres for injection) and Ruiketuo® (risperidone microspheres for injection (II)) were renewed and continue to be included in the National Reimbursement Drug List.